SCHEMBL933875

SCHEMBL933875

C#Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.61
TSHR P16473 2/20 0.48
MAPK1 P28482 1/20 0.48
GRM5 P41594 3/20 0.44
CES2 O00748 1/20 0.44
MGLL Q99685 1/20 0.44
FFAR1 O14842 1/20 0.43
ALDH1A1 P00352 2/20 0.42
ACP3 P15309 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
MIF P14174 1/20 0.41
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890941 1.00 PTPN1 (0.61) PTPN1TSHRMAPK1GRM5CES2
Phenylacetylene SCHEMBL28207264 0.94 PTPN1 (0.60) PTPN1TSHRMAPK1GRM5CES2
SCHEMBL11239236 0.89 PTPN1 (0.51) PTPN1TSHRMAPK1GRM5FFAR1
SCHEMBL11224511 0.86 PTPN1 (0.49) PTPN1TSHRMAPK1ALDH1A1
SCHEMBL11234512 0.85 PTPN1 (0.48) PTPN1TSHRMAPK1ALDH1A1
SCHEMBL10535262 0.83 PTPN1 (0.57) PTPN1TSHRMAPK1GRM5FFAR1
SCHEMBL30873473 0.82 GRM5 (0.58) PTPN1TSHRMAPK1GRM5CES2
SCHEMBL2273427 0.82 TSHR (0.52) PTPN1TSHRMAPK1GRM5CES2
SCHEMBL17729320 0.79 PTPN1 (0.49) PTPN1TSHRMAPK1GRM5CA12
SCHEMBL695156 0.78 TSHR (0.48) PTPN1TSHRMAPK1GRM5CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119395917-A Preparation method of anti-mode polymer stabilized cholesteric liquid crystal intelligent window with low energy consumption and high privacy 哈尔滨工业大学 2025-02-07 CN claimed
CN-117624520-A Trifluoromethyl modified pyrenyl covalent organic framework material, and preparation method and application thereof 中国石油大学(华东) 2024-03-01 CN claimed
CN-116082390-A Preparation method of diethyl zinc catalyzed organosilane compound 北京理工大学 2023-05-09 CN claimed
CN-114874088-A Acetylenic acid and preparation method thereof 中国科学院上海高等研究院 2022-08-09 CN claimed
EP-3051946-B1 USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS BAYER CROPSCIENCE AG (DE) 2017-11-29 EP claimed
EP-2013171-B1 PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER S DISEASE MERCK SHARP & DOHME (GB) 2013-05-15 EP claimed
EP-1599201-B1 SELECTIVE NON-STEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS MERCK SHARP & DOHME (US) 2010-04-14 EP claimed
EP-2170805-A2 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF Amgen Inc. (US) 2010-04-07 EP claimed
EP-1664027-B1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2009-12-30 EP claimed
WO-2009002427-A2 METHODS OF SYNTHESIZING CINACALCET AND SALTS THEREOF AMGEN INC. (US) 2008-12-31 WO claimed
EP-1664023-B1 SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2008-08-13 EP claimed
EP-1244617-B1 SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE ORTHO MCNEIL PHARM INC (US) 2005-02-16 EP claimed
EP-0922050-B1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LAB (US) 2003-07-30 EP claimed
EP-1053224-B1 BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT AVENTIS PHARMA GMBH (DE) 2002-08-21 EP claimed
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-06-12 US disclosed
WO-2025034034-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER OR TUMORS COMPRISING SAME 주식회사 대웅제약 2025-02-13 WO disclosed
CN-119395917-A Preparation method of anti-mode polymer stabilized cholesteric liquid crystal intelligent window with low energy consumption and high privacy 哈尔滨工业大学 2025-02-07 CN disclosed
EP-1274424-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-15 EP disclosed
WO-2001078723-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-25 WO disclosed
WO-1991006533-A1 NOVEL PROCESS FOR MANUFACTURING COMPOUNDS WITH VALUABLE PHARMACOLOGICAL PROPERTIES AND NEW INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF THESE COMPOUNDS BOEHRINGER MANNHEIM GMBH (DE) 1991-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186408-A1 TREATMENT OF PHARMACORESISTANT EPILEPSY CNR1, CNR2, CYP2J2 PTPN1 3657/4885TSHR 892/4885MAPK1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.